BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1186 related articles for article (PubMed ID: 15613446)

  • 1. Epidermal growth factor receptor inhibition strategies in oncology.
    Harari PM
    Endocr Relat Cancer; 2004 Dec; 11(4):689-708. PubMed ID: 15613446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers.
    Vokes EE; Chu E
    Oncology (Williston Park); 2006 Apr; 20(5 Suppl 2):15-25. PubMed ID: 16736979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
    Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
    Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidermal growth factor receptor targeting in cancer: a review of trends and strategies.
    Yewale C; Baradia D; Vhora I; Patil S; Misra A
    Biomaterials; 2013 Nov; 34(34):8690-707. PubMed ID: 23953842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiation combined with EGFR signal inhibitors: head and neck cancer focus.
    Harari PM; Huang S
    Semin Radiat Oncol; 2006 Jan; 16(1):38-44. PubMed ID: 16378905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors. Similarities and differences.
    Dassonville O; Bozec A; Fischel JL; Milano G
    Crit Rev Oncol Hematol; 2007 Apr; 62(1):53-61. PubMed ID: 17324578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidermal growth factor receptor targeting in cancer.
    Mendelsohn J; Baselga J
    Semin Oncol; 2006 Aug; 33(4):369-85. PubMed ID: 16890793
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
    Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
    Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.
    Harding J; Burtness B
    Drugs Today (Barc); 2005 Feb; 41(2):107-27. PubMed ID: 15821783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas.
    Karamouzis MV; Grandis JR; Argiris A
    JAMA; 2007 Jul; 298(1):70-82. PubMed ID: 17609492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of the epidermal growth factor receptor in combined modality treatment for locally advanced non-small cell lung cancer.
    Ready N
    Semin Oncol; 2005 Apr; 32(2 Suppl 3):S35-41. PubMed ID: 16015534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidermal growth factor receptor as a therapeutic target in colorectal cancer.
    Cohen RB
    Clin Colorectal Cancer; 2003 Feb; 2(4):246-51. PubMed ID: 12620146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cutaneous reactions to anticancer agents targeting the epidermal growth factor receptor: a dermatology-oncology perspective.
    Lacouture ME; Melosky BL
    Skin Therapy Lett; 2007; 12(6):1-5. PubMed ID: 17762902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidermal growth factor receptor as a target for chemotherapy.
    Vallbohmer D; Lenz HJ
    Clin Colorectal Cancer; 2005 Apr; 5 Suppl 1():S19-27. PubMed ID: 15871762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidermal growth factor receptor (EGFR) targeted therapies in non-small cell lung cancer (NSCLC).
    Metro G; Finocchiaro G; Toschi L; Bartolini S; Magrini E; Cancellieri A; Trisolini R; Castaldini L; Tallini G; Crino L; Cappuzzo F
    Rev Recent Clin Trials; 2006 Jan; 1(1):1-13. PubMed ID: 18393776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EGFR inhibition in NSCLC: the emerging role of cetuximab.
    Herbst RS
    J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S41-51. PubMed ID: 19780245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer.
    Baselga J; Arteaga CL
    J Clin Oncol; 2005 Apr; 23(11):2445-59. PubMed ID: 15753456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidermal growth factor receptor expression, signal pathway, and inhibitors in non-small cell lung cancer.
    Bunn PA; Franklin W
    Semin Oncol; 2002 Oct; 29(5 Suppl 14):38-44. PubMed ID: 12422312
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.
    Erjala K; Sundvall M; Junttila TT; Zhang N; Savisalo M; Mali P; Kulmala J; Pulkkinen J; Grenman R; Elenius K
    Clin Cancer Res; 2006 Jul; 12(13):4103-11. PubMed ID: 16818711
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Molecular target-based cancer therapy: epidermal growth factor receptor inhibitors].
    Tamura T
    Nihon Geka Gakkai Zasshi; 2002 Feb; 103(2):233-6. PubMed ID: 11904986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 60.